



## Joint Working Executive Summary

Published on [www.bayer.co.uk](http://www.bayer.co.uk)

---

<b>Project title</b>	Southampton Andrology Virtual Outreach Project
<b>Project partners</b>	University Hospitals Southampton NHS Foundation Trust Bayer plc
<b>Project summary</b>	<p>The aim of the project will be to expand the capacity of the andrology service at University Hospitals Southampton to provide increased support for patients and GP practices across a wide geographical footprint, including Hampshire, Isle of Wight, East Dorset and South Wiltshire.</p> <p>The expanded service will establish specialist testosterone deficiency clinics, staffed by appropriately skilled HCPs, providing both face to face and telephone follow up for patients to enable optimal management.</p> <p>The service will liaise with diabetic clinics in both primary and secondary care to increase screening and diagnosis in men over 50 with type II diabetes. The provision of the service in multiple settings will reduce the demand on secondary care and enable more patients to access screening, diagnosis and treatment for testosterone deficiency.</p> <p>The service will raise awareness with HCPs of the condition and the treatments available, as well as where to go for the management of their patients with the condition. This will be conducted using a dedicated webinar platform.</p> <p>The service will work closely with local healthcare systems to deliver integrated care with the patient at the centre.</p>
<b>Expected benefits to patients, the NHS and Bayer</b>	<p><b>Benefits for Patients:</b></p> <ul style="list-style-type: none"><li>• Increased access to screening and treatment for testosterone deficiency</li><li>• Care closer to home by accessing treatments in community setting</li><li>• Increased recognition and support for an underdiagnosed condition</li><li>• Improved outcomes for patients with diabetes</li></ul> <p><b>Benefits for the NHS:</b></p> <ul style="list-style-type: none"><li>• Redesigning services in line with new models of care following the Multispecialty Community Provider model</li><li>• Reducing demand on primary and secondary care</li><li>• Reducing variation in access to care</li><li>• Up-skilling primary care</li><li>• Improving outcomes for diabetes patients</li></ul>

	<ul style="list-style-type: none"> <li>• Accessing national funding streams by improving patient satisfaction with services</li> </ul> <p><b>Benefits for Bayer:</b></p> <ul style="list-style-type: none"> <li>• The opportunity to work with a Centre of Excellence to redesign services to improve patient outcomes</li> <li>• Increased opportunity for the use of medicines to treat hypogonadism, of which Bayer has one</li> <li>• The opportunity to partner with the NHS to produce a publication of an exemplar framework for andrology services</li> <li>• An increase in understanding of the range of co-morbidities associated with diabetes and testosterone deficiency</li> </ul>
<b>Start date</b>	June 2019

Date of Preparation: January 2021

CF Document Number: PP-PF-MENH-GB-0012